Step Pharma CEO Andrew Parker

Step Phar­ma clos­es $41M round to take en­zyme tar­get­ing lead pro­gram in­to ear­ly-stage tri­al for T cell ma­lig­nan­cies

The search for bet­ter T and B cell ther­a­pies have ab­sorbed bil­lions in R&D funds from some of the biggest drug­mak­ers in the world. A French biotech thinks it could have a hy­per-fo­cused ap­proach to T and B cell ma­lig­nan­cies, and it’s tak­ing home a de­cent-sized check to race to the clin­ic.

Step Phar­ma has bagged $41.5 mil­lion in fund­ing to take its lead CTPS1 in­hibitor in­to clin­i­cal tri­als for T cell ma­lig­nan­cies by the first quar­ter of 2022, the French biotech said Wednes­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.